Literature DB >> 19620780

Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.

Laurence Zitvogel1, Guido Kroemer.   

Abstract

Conventional chemotherapeutics may induce immunogenic cancer cell death or stimulate immune effectors via so-called off-target effects. The study by Besch et al. in this issue of the JCI now demonstrates that agents designed to stimulate the innate immune system by activating intracellular pattern recognition receptors can kill cancer cells in a direct, cell-autonomous fashion (see the related article beginning on page 2399). The authors show that ligation of viral RNA sensors, such as RIG-I or MDA-5, by viral RNA mimetics triggers mitochondrial apoptosis in human melanoma cells in an IFN-independent fashion. The data suggest that tumor cell killing and immunostimulation may synergize for optimal anticancer immunochemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19620780      PMCID: PMC2719931          DOI: 10.1172/JCI39991

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

Review 1.  BCG immunotherapy of bladder cancer: 20 years on.

Authors:  A B Alexandroff; A M Jackson; M A O'Donnell; K James
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

2.  Toll-like receptor 3 expressed by melanoma cells as a target for therapy?

Authors:  Bruno Salaun; Serge Lebecque; Sampsa Matikainen; Donata Rimoldi; Pedro Romero
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

3.  Inhibition of cancer cell growth by polyinosinic-polycytidylic acid/cationic liposome complex: a new biological activity.

Authors:  K Hirabayashi; J Yano; T Inoue; T Yamaguchi; K Tanigawara; G E Smyth; K Ishiyama; T Ohgi; K Kimura; T Irimura
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

4.  TLR3 can directly trigger apoptosis in human cancer cells.

Authors:  Bruno Salaun; Isabelle Coste; Marie-Clotilde Rissoan; Serge J Lebecque; Toufic Renno
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

5.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells.

Authors:  Robert Besch; Hendrik Poeck; Tobias Hohenauer; Daniela Senft; Georg Häcker; Carola Berking; Veit Hornung; Stefan Endres; Thomas Ruzicka; Simon Rothenfusser; Gunther Hartmann
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

Review 6.  MDA5/RIG-I and virus recognition.

Authors:  Osamu Takeuchi; Shizuo Akira
Journal:  Curr Opin Immunol       Date:  2008-02-12       Impact factor: 7.486

Review 7.  The anticancer immune response: indispensable for therapeutic success?

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Fabrice André; Antoine Tesniere; Guido Kroemer
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

8.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Authors:  Christophe Borg; Magali Terme; Julien Taïeb; Cédric Ménard; Caroline Flament; Caroline Robert; Koji Maruyama; Hiro Wakasugi; Eric Angevin; Kris Thielemans; Axel Le Cesne; Véronique Chung-Scott; Vladimir Lazar; Isabelle Tchou; Florent Crépineau; François Lemoine; Jacky Bernard; Jonhantan A Fletcher; Ali Turhan; Jean-Yves Blay; Alain Spatz; Jean-François Emile; Michael C Heinrich; Salah Mécheri; Thomas Tursz; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 9.  Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies.

Authors:  Lionel Apetoh; Antoine Tesniere; François Ghiringhelli; Guido Kroemer; Laurence Zitvogel
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

Review 10.  Imiquimod: an immune response modifier in the treatment of precancerous skin lesions and skin cancer.

Authors:  Evangelia Papadavid; Alexandros J Stratigos; Matthew E Falagas
Journal:  Expert Opin Pharmacother       Date:  2007-08       Impact factor: 3.889

View more
  26 in total

1.  Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

Authors:  Douglas W McMillin; Jake Delmore; Joseph M Negri; Matthew Vanneman; Shohei Koyama; Robert L Schlossman; Nikhil C Munshi; Jacob Laubach; Paul G Richardson; Glenn Dranoff; Kenneth C Anderson; Constantine S Mitsiades
Journal:  Blood       Date:  2012-01-30       Impact factor: 22.113

Review 2.  Pattern recognition of viral nucleic acids by RIG-I-like helicases.

Authors:  Andreas Schmidt; Stefan Endres; Simon Rothenfusser
Journal:  J Mol Med (Berl)       Date:  2010-09-04       Impact factor: 4.599

3.  Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

Authors:  W Joost Lesterhuis; Cornelis J A Punt; Stanleyson V Hato; Dagmar Eleveld-Trancikova; Bastiaan J H Jansen; Stefan Nierkens; Gerty Schreibelt; Annemiek de Boer; Carla M L Van Herpen; Johannes H Kaanders; Johan H J M van Krieken; Gosse J Adema; Carl G Figdor; I Jolanda M de Vries
Journal:  J Clin Invest       Date:  2011-07-18       Impact factor: 14.808

Review 4.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

5.  The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.

Authors:  Begoña Comin-Anduix; Thinle Chodon; Hooman Sazegar; Douglas Matsunaga; Stephen Mock; Jason Jalil; Helena Escuin-Ordinas; Bartosz Chmielowski; Richard C Koya; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

6.  High-throughput approaches to discover novel immunomodulatory agents for cancer.

Authors:  Douglas W McMillin; Constantine S Mitsiades
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

7.  Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Authors:  Assia L Angelova; Svitlana P Grekova; Anette Heller; Olga Kuhlmann; Esther Soyka; Thomas Giese; Marc Aprahamian; Gaétan Bour; Sven Rüffer; Celina Cziepluch; Laurent Daeffler; Jean Rommelaere; Jens Werner; Zahari Raykov; Nathalia A Giese
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 8.  Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.

Authors:  Margaret E Gatti-Mays; Jason M Redman; Julie M Collins; Marijo Bilusic
Journal:  Hum Vaccin Immunother       Date:  2017-08-31       Impact factor: 3.452

Review 9.  The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

Authors:  Douglas W McMillin; Joseph M Negri; Constantine S Mitsiades
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 10.  Deciphering and reversing tumor immune suppression.

Authors:  Greg T Motz; George Coukos
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.